Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096025 · ClinicalTrials.gov registry record
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
A clinical trial of Streptococcus Pneumoniae, sponsored by Methodist Health System.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06096025: Active study of Streptococcus Pneumoniae, sponsored by Methodist Health System.
NCT06096025 is a study of Streptococcus Pneumoniae that is active but no longer recruiting, run by Methodist Health System. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06096025, a study of Streptococcus Pneumoniae, is active but no longer recruiting, sponsored by Methodist Health System.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.
Primary Outcome
hospital readmission with streptococcal pneumonia, bacteremia, endocarditis, meningitis, and lung abscess within 30 days of antibiotic completion
Conditions Studied
Interventions
- DRUG pneumoniae bacteremia therapy
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2026-06-23 |
What the registry record for NCT06096025 still lists
NCT06096025 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Streptococcus Pneumoniae appearing as the primary indexed condition, and to 1 intervention - of which pneumoniae bacteremia therapy is the first listed.
NCT06096025 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06096025 about?
NCT06096025 is a clinical study titled "Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections". Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens a...
What is the current status of trial NCT06096025?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2023-06-23. Estimated completion is 2026-06-23.
What conditions does trial NCT06096025 study?
This clinical trial studies the following conditions: Streptococcus Pneumoniae.
What interventions are being tested in trial NCT06096025?
The interventions under investigation include: pneumoniae bacteremia therapy (DRUG).
Who is sponsoring clinical trial NCT06096025?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096025 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Streptococcus Pneumoniae
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI